http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
( Chien-lung Hsu ),( Han-yu Lin ) 한국인터넷정보학회 2013 KSII Transactions on Internet and Information Syst Vol.7 No.11
Key exposure is a major threat to secure cryptosystems. To mitigate the impact caused by key-compromise attacks, a key-insulated cryptographic mechanism is a better alternative. For securing the large message communication in peer-to-peer networks, in this paper, we propose the first novel identity-based key-insulated encryption (IB-KIE) scheme with message linkages. Our scheme has the properties of unbounded time periods and random-access key-updates. In the proposed scheme, each client can periodically update his private key while the corresponding public one remains unchanged. The essential security assumption of our proposed scheme is based on the well-known bilinear Diffie-Hellman problem (BDHP). To ensure the practical feasibility, we also formally prove that the proposed scheme achieves the security requirement of confidentiality against indistinguishability under adaptive chosen-ciphertext attacks (IND-CCA2) in the random oracle model.
Chien-Tai Hong,Lung Chan,Chaur-Jong Hu,Chien-Min Lin,Chien-Yeh Hsu,Ming-Chin Lin 한국유방암학회 2017 Journal of breast cancer Vol.20 No.4
Purpose: Whether tamoxifen affects the risk of neurodegenerative disease is controversial. This nationwide population-based study investigated the risk of Parkinson’s disease (PD) associated with tamoxifen treatment in female patients with breast cancer using Taiwan’s National Health Insurance Research Database. Methods: A total of 5,185 and 5,592 female patients with breast cancer who did and did not, respectively, receive tamoxifen treatment between 2000 and 2009 were included in the study. Patients who subsequently developed PD were identified. A Cox proportional hazards model was used to compare the risk of PD between the aforementioned groups. Results: Tamoxifen did not significantly increase the crude rate of developing PD in female patients with breast cancer (tamoxifen group, 16/5,169; non-tamoxifen group, 11/5,581; p=0.246). Tamoxifen did not significantly increase the adjusted hazard ratio (aHR) for subsequently developing PD (aHR, 1.310; 95% confidence interval [CI], 0.605–2.837; p= 0.494). However, tamoxifen significantly increased the risk of PD among patients followed up for more than 6 years (aHR, 2.435; 95% CI, 1.008–5.882; p=0.048). Conclusion: Tamoxifen treatment may increase the risk of PD in Taiwanese female patients with breast cancer more than 6 years after the initiation of treatment.
( Ming-lung Yu ),( Chao-hung Hung ),( Yi-hsiang Huang ),( Cheng-yuan Peng ),( Chun-yen Lin ),( Pin-nan Cheng ),( Rong-nan Chien ),( Shih-jer Hsu ),( Chen-hua Liu ),( Jee-fu Huang ),( Chung-feng Huang 대한간학회 2018 춘·추계 학술대회 (KASL) Vol.2018 No.1
Aims: The current study aims to elucidate the treatment efficacy (defined as undetectable HCV RNA throughout 12 weeks of post-treatment follow-up, SVR12) and safety DCV/ASV plus ribavirin for 12 weeks in HCV-1b patients without NS5A RAS. Methods: This is a single-arm, open-label phase 2 study. Seventy directly acting antivirals (DAA)-naïve HCV-1b patients without L31/Y93 RAS are planned to receive daclatasvir (60 mg/ day) and asunaprevir (100 mg twice daily) plus weight-based ribavirin (1000-1200 mg/day) for 12 weeks. After treatment they were followed up for 12 weeks. Results: As of 31 Oct 2017, 58 eligible patients are allocated to treatment, with a mean age of 59.3 years and female predominance (67.2%, 39/58). The mean HCV RNA was 5.87+0.77 log10 IU/mL; 23 patients (39.7 %) had significant hepatic fibrosis (>F2). In the modified intention-to-treat analysis, the rate of undetectable HCV at week 1, week 2, week 4, week 8 and endof- treatment was 25 % (14/56), 84.8 % (39/46), 100 % (46/46), 100 % (38/38) and 100 % (27/27), respectively. Undetectable HCV RNA were observed in all of the patients with HCV RNA assessable 4 weeks (SVR4, 18/18) and 12 weeks (SVR12, 12/12) post treatment. None of the 18 patients who completed the 12-week treatment experienced relapse during post-treatment follow-up. The most common adverse event was fatigue (78.3 %), followed by pruritus (65.2 %) and dizziness (52.2 %), of which were considered as ribavirin related. None of the participating subjects withdrew treatment or follow-up throughout the trial peroid. Three serious adverse events were reported which included urosepsis, appendicitis and left ureteral stone. All were unrelated to the investigating drugs. Conclusions: 12 weeks of DCV/ASV plus ribavirin was highly effective and safe in HCV-1b patients without NS5A RAS in the interim analysis. The satisfactory results would be anticipated in the full patient set.
Photocatalytic study of Zinc Oxide with bismuth doping prepared by spray pyrolysis
Lin, Tzu-Yang,Hsu, Yu-Ting,Lan, Wen-How,Huang, Chien-Jung,Chen, Lung-Chien,Huang, Yu-Hsuan,Lin, Jia-Ching,Chang, Kuo-Jen,Lin, Wen-Jen,Huang, Kai-Feng Techno-Press 2015 Advances in nano research Vol.3 No.3
The unintentionally doped and bismuth (Bi) doped zinc oxide (ZnO) films were prepared by spray pyrolysis at $450^{\circ}C$ with zinc acetate and bismuth nitrate precursor. The n-type conduction with concentration $6.13{\times}10^{16}cm^{-3}$ can be observed for the unintentionally doped ZnO. With the increasing of bismuth nitrate concentration in precursor, the p-type conduction can be observed. The p-type concentration $4.44{\times}10^{17}cm^{-3}$ can be achieved for the film with the Bi/Zn atomic ratio 5% in the precursor. The photoluminescence spectroscopy with HeCd laser light source was studied for films with different Bi doping. The photocatalytic activity for the unintentionally doped and Bi-doped ZnO films was studied through the photodegradation of Congo red under UV light illumination. The effects of different Bi contents on photocatalytic activity are studied and discussed. Results show that appropriate Bi doping in ZnO can increase photocatalytic activity.
Chi-I Tuan,Ting-Chien Chen,Yi-Lung Yeh,Lang-Fong Hsu 한국화학공학회 2012 Korean Journal of Chemical Engineering Vol.29 No.3
This research investigated optimal energy utilization with pinch technology based on an actual gelatin production factory using a three-effect evaporator (TEE). A TEE is a well-known device used extensively when concentrating process fluid with large amounts of boiler steam. Under ideal energy use conditions, the exhaust heat can be recovered with the addition of a heat pump system. The study results showed that the original energy demand and discharge of the TEE were 1,736.2 and 1,733.2 kWh, respectively. Simulating the pinch technology use, the energy demand and discharge decreased to 1,531.5 and 1,527.7 kWh, respectively. When the heat pump was used to recover the exhaust heat, 324 kL per annum of fuel oil was saved, while electricity use increased 131 kWh. The total investment cost was 86,550 US$, but the total annual operation cost could save up to 166,421 US$. The net present value was estimated to be 544,316 US$ with a 5-year equipment operation. The investment expense could be completely recovered within a seven-month remuneration period.
Desmond Y. H. Yap,Kevin S. H. Liu,Yu-Chun Hsu,Grace L. H. Wong,Ming-Chang Tsai,Chien-Hung Chen,Ching-Sheng Hsu,Yee Tak Hui,Michael K. K. Li,Chen-Hua Liu,Yee-Man Kan,Ming-Lung Yu,Man-Fung Yuen 대한간학회 2020 Clinical and Molecular Hepatology(대한간학회지) Vol.26 No.4
Background/Aims: Data on treatment efficacy and safety of glecaprevir/pibrentasvir (GLE/PIB) for chronic hepatitis C virus (HCV) infection in Asian patients with severe renal impairment are limited. This study aimed to study the treatment and side effects of GLE/PIB in these patients infected with non-1 genotype (GT) HCV. Methods: We prospectively recruited patients with Child’s A cirrhosis and eGFR <30 mL/min/1.73 m2 in Hong Kong and Taiwan during 2017–2018 to receive GLE/PIB treatment. Results: Twenty-one patients (GT2, n=7; GT3, n=6; and GT6, n=8) received GLE/PIB for 11.2±1.8 weeks. All except one were treatment-naïve. GLE/PIB was initiated in 16 patients while on dialysis (seven on peritoneal dialysis [PD] and nine on hemodialysis) and in five patients before dialysis. One patient died of PD-related peritonitis during treatment and two were lost to follow up. The SVR12 rate in the remaining 18 patients was 100%. All patients achieved undetectable levels at 4-, 12-, 24- and 48-week after treatment. Patients with deranged alanine aminotransferase showed normalization after 4 weeks and the response was sustained for 48 weeks. No significant adverse event was observed. Conclusions: GLE/PIB treatment was associated with high efficacy and tolerability in HCV-infected patients with severe renal impairment.